Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA – Get Free Report) have been assigned a consensus recommendation of “Buy” from the eight research firms that are currently covering the firm, MarketBeat Ratings reports. Eight equities research analysts have rated the stock with a buy recommendation. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $6.88.
Several research analysts have weighed in on the company. Piper Sandler assumed coverage on Taysha Gene Therapies in a research report on Tuesday, April 9th. They set an “overweight” rating and a $9.00 price target on the stock. Chardan Capital boosted their price target on Taysha Gene Therapies from $5.00 to $7.00 and gave the stock a “buy” rating in a research report on Thursday, March 21st. JMP Securities reissued a “market outperform” rating and set a $5.00 target price on shares of Taysha Gene Therapies in a report on Wednesday, March 20th. Needham & Company LLC reissued a “buy” rating and set a $7.00 target price on shares of Taysha Gene Therapies in a report on Thursday, April 11th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $7.00 target price on shares of Taysha Gene Therapies in a report on Thursday, April 18th.
Read Our Latest Stock Report on TSHA
Institutional Trading of Taysha Gene Therapies
Taysha Gene Therapies Stock Up 3.9 %
Shares of Taysha Gene Therapies stock opened at $2.39 on Friday. The business’s 50 day simple moving average is $2.64 and its 200 day simple moving average is $2.09. Taysha Gene Therapies has a 52-week low of $0.50 and a 52-week high of $3.89. The firm has a market cap of $446.98 million, a PE ratio of -3.57 and a beta of 0.29. The company has a debt-to-equity ratio of 0.54, a quick ratio of 4.08 and a current ratio of 4.08.
Taysha Gene Therapies (NASDAQ:TSHA – Get Free Report) last announced its earnings results on Tuesday, March 19th. The company reported $0.35 earnings per share (EPS) for the quarter. The firm had revenue of $3.60 million during the quarter, compared to analyst estimates of $4.75 million. On average, analysts predict that Taysha Gene Therapies will post -0.39 earnings per share for the current fiscal year.
About Taysha Gene Therapies
Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.
Recommended Stories
- Five stocks we like better than Taysha Gene Therapies
- What is the S&P 500 and How It is Distinct from Other Indexes
- 3 Stocks Leading the U.S. Agriculture Comeback
- Using the MarketBeat Dividend Tax Calculator
- How to Use Put Debit Spreads to Profit From Falling Stocks
- What is a Stock Market Index and How Do You Use Them?
- Alphabet Changes the Narrative with Its First-Ever Dividend
Receive News & Ratings for Taysha Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taysha Gene Therapies and related companies with MarketBeat.com's FREE daily email newsletter.